Enclosed financial results for the quarter and year ended 31st March, 2026.
HALEOSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Haleos Labs reported FY26 standalone revenue of Rs 30,099 lakh, down from Rs 33,337 lakh in FY25 — a revenue decline of approximately 10%. Standalone net profit fell to Rs 1,778 lakh from Rs 2,137 lakh, a decline of about 17%. Consolidated revenue was Rs 33,379 lakh (vs Rs 34,472 lakh) and consolidated net profit was Rs 1,780 lakh (vs Rs 1,873 lakh). The board declared a dividend of Rs 1.50 per share (15%). Statutory auditors Rambabu & Co. issued an unmodified opinion on both standalone and consolidated results. The company announced a change in statutory auditors — Suryanarayana & Suresh is proposed to replace Rambabu & Co. subject to shareholder approval. An independent director, Mrs. Sundaramma Patibandla, resigned and the board reconstituted its sub-committees. Related party transactions for the half-year were disclosed including loans and transactions with subsidiary Mahi Drugs Private Limited and entities where KMPs exercise significant influence. The company is seeking shareholder approval for material related party transactions for FY27 via postal ballot.
The revenue and profit decline may concern investors in the near term, though the company maintains positive operating cash flows and clean audit opinions. The dividend declaration provides some return to shareholders despite lower profitability. The auditor change and director resignation are governance-related items shareholders should monitor.